Doerr, Fabian
George, Julie
Schmitt, Anna
Beleggia, Filippo
Rehkämper, Tim
Hermann, Sarah
Walter, Vonn
Weber, Jean-Philip
Thomas, Roman K.
Wittersheim, Maike
Büttner, Reinhard
Persigehl, Thorsten
Reinhardt, H. Christian
Article History
Received: 25 August 2017
Accepted: 2 November 2017
First Online: 14 November 2017
Competing Interests
: H.C.R. received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex and Merck. R.K.T. is a founder of NEO New Oncology GmbH, now part of Siemens Healthcare. R.K.T. received consulting and lecture fees (Merck, Roche, Lilly, Boehringer Ingelheim, Astra-Zeneca, Daiichi-Sankyo, MSD, NEO New Oncology, Puma, Clovis). The remaining authors declare no competing financial interest.